Ausgabe 6/2019
Inhalt (12 Artikel)
Chronic Myeloid Leukemias (G Saglio, Section Editor)
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?
Robert Peter Gale, Jane Apperley
Chronic Myeloid Leukemias (G Saglio, Section Editor)
Early Management of CML
Naranie Shanmuganathan, Timothy P. Hughes
Open Access
Chronic Myeloid Leukemias (G Saglio, Section Editor)
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
Florence Rabian, Etienne Lengline, Delphine Rea
Chronic Myeloid Leukemias (G Saglio, Section Editor)
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
Naranie Shanmuganathan, Susan Branford
Open Access
Chronic Myeloid Leukemias (G Saglio, Section Editor)
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
Richard E. Clark
Acute Myeloid Leukemias (H Erba, Section Editor)
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Minas P. Economides, David Rizzieri, Naveen Pemmaraju
Acute Myeloid Leukemias (H Erba, Section Editor)
Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper
Kah Poh Loh, Maya Abdallah, Anita J. Kumar, Nina R Neuendorff, Saurabh Dahiya, Heidi D. Klepin
Myelodysplastic Syndromes (M Savona, Section Editor)
The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)
David P. Steensma
Myelodysplastic Syndromes (M Savona, Section Editor)
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
Andrew T. Kuykendall, Eric Padron
Myelodysplastic Syndromes (M Savona, Section Editor)
Mutation-Driven Therapy in MDS
David M. Swoboda, David A. Sallman
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Driving the CAR to the Bone Marrow Transplant Program
Hema Dave, Lauren Jerkins, Patrick J Hanley, Catherine M Bollard, David Jacobsohn
T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
Geoffrey Shouse, Liana Nikolaenko